Autres langues AdAlta Limited

Actions

Marché Fermé - Australian S.E. Autres places de cotation 08:10:21 24/06/2024			Varia. 5j.	Varia. 1 janv.
0,026 ^AUD	+4,00%		0,00%	+8,33%

08/04	AdAlta explore la possibilité d'une coentreprise d'immunothérapies anticancéreuses pour le marché occidental	MT
26/02	AdAlta Limited publie ses résultats pour le semestre clos le 31 décembre 2023	CI

AdAlta Raises AU$1.9 Million from 1ADOA Options	03/06
AdAlta Signs Master Services Agreement with Cell Therapies; Shares Up 4%	13/05
AdAlta Secures Up to AU$3.7 Million for MOU, i-body Programs	29/04
AdAlta Explores Cancer Immunotherapies Joint Venture for Western Market	08/04
AdAlta delivers positive Phase I Extension Study results for AD-214	08/03
AdAlta Limited Reports Earnings Results for the Half Year Ended December 31, 2023	26/02
AdAlta-La Trobe University Collab Discovers New i-Bodies for Malaria Treatment; Shares Climb 4%	19/12
Adalta Posts Upbeat Results from Phase I Trial of Fibrotic Disease Drug	22/11
AdAlta closes oversubscribed $1.65 million raise	08/11
AdAlta Raises AU$1.7 Million Via Oversubscribed Placement; Shares Down 9%	07/11
AdAlta to Seeks AU$1.2 Million from Share Placement	03/11
AdAlta making material progress on partnering talks	23/10/23
AdAlta Receives AU$2.4 Million R&D Tax Rebate	18/10/23
AdAlta says new AD-214 dosing models enhance partnering potential	26/09/23
AdAlta completes enrolment for AD-214 fibrosis safety trial	21/09/23
Adalta Completes Enrollment for Phase 1 Study on Fibrotic Disease Medication; Shares Fall 9%	20/09/23
AdAlta Limited Reports Earnings Results for the Full Year Ended June 30, 2023	25/08/23
AdAlta to Present at August 24th Virtual Investor Summit	16/08/23
AdAlta back in the clinic with AD-214	07/08/23
Adalta Carries Out First Dosing in Phase One Extension Study of Fibrotic Disease Medication; Shares Jump 4%	04/08/23

Aucun résultat pour cette recherche